Eulav Asset Management Revance Therapeutics, Inc. Call Options Transaction History
Eulav Asset Management
- $3.64 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RVNC
# of Institutions
214Shares Held
83.4MCall Options Held
656KPut Options Held
424K-
Capital World Investors Los Angeles, CA13.9MShares$35.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.31MShares$18.8 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA6.28MShares$16.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.4MShares$13.9 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.25MShares$13.5 Million3.02% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...